<DOC>
	<DOCNO>NCT00425646</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Imatinib mesylate bevacizumab may also stop growth tumor cell block blood flow tumor . Giving imatinib mesylate together bevacizumab maintenance therapy may stop non-small cell lung cancer grow come back . PURPOSE : This phase II trial study well give imatinib mesylate together bevacizumab first-line chemotherapy bevacizumab work treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Imatinib Mesylate Bevacizumab After First-Line Chemotherapy Bevacizumab Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical efficacy maintenance therapy comprise imatinib mesylate bevacizumab completion first-line , platinum-based chemotherapy bevacizumab , term progression-free survival , patient stage IIIB IV non-small cell lung cancer . Secondary - Assess safety profile regimen patient . OUTLINE : This open-label , multicenter study . Patients receive oral imatinib mesylate twice daily day 1-21 bevacizumab IV 30 minute day 1 . Treatment repeat every 21 day 1 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Stage IIIB ( pleural effusion ) stage IV disease No predominately squamous cell carcinoma Mixed tumor categorize predominant cell type Must complete 4 course platinumbased , doublet chemotherapy bevacizumab* , disease progression , meet follow criterion : Platinum agent may include carboplatin cisplatin Second agent may include paclitaxel , docetaxel , gemcitabine hydrochloride , vinorelbine ditartrate , pemetrexed disodium A change platinum doublet acceptable provide follow true : Basis change toxicity rather disease progression Total number course platinum doublet plus bevacizumab 4 At least 3 4 course must include bevacizumab NOTE : *Patients age 70 may complete 4 course singleagent chemotherapy plus bevacizumab ; single agent chemotherapy may include paclitaxel , docetaxel , gemcitabine hydrochloride , vinorelbine ditartrate , pemetrexed disodium No brain metastasis brain MRI head CT scan PATIENT CHARACTERISTICS : ECOG performance status 01 Bilirubin ≤ 1.25 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN Absolute neutrophil count ≥ 1500/mm³ Platelet count ≥ 100,000/mm³ INR ≤ 1.5 time ULN Urine protein : creatinine ratio ≤ 1 Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month completion study treatment No history gross hemoptysis ( define &gt; ½ teaspoon bright red blood ) No inadequately control hypertension ( define blood pressure &gt; 150/100 mm Hg antihypertensive medication ) No significant traumatic injury within past 28 day No condition require continuous administration systemic corticosteroid No medical condition would preclude study treatment No medical comorbidities , include follow : Unstable angina Congestive heart failure ≥ grade 2 Myocardial infarction within past 6 month Stroke within past 6 month Peripheral vascular disease ≥ grade 2 within past 6 month PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior systemic chemotherapy metastatic setting , except 4 course platinumbased , doublet chemotherapy plus bevacizumab firstline set Prior adjuvant , neoadjuvant , combine modality chemoradiation localize nonsmall cell lung cancer allow provide ≥ 6 month elapse metastatic recurrence At least 28 day since prior major surgical procedure No prior antiangiogenic drug , include AMG 706 , CP547 , 632 , vatalanib , AZD2171 , thalidomide , sorafenib tosylate , sunitinib malate No concurrent investigational drug No concurrent grapefruit juice product contain grapefruit No concurrent anticancer agent , include chemotherapy biological agent No concurrent major surgical procedure No concurrent therapeutic coagulation comprise warfarin , heparin , low molecular weight heparin Lowdose warfarin ( e.g. , 1 mg/day ) prophylaxis central venous catheter thrombosis allow No chronic daily acetylsalicylic acid ( &gt; 325 mg/day ) fulldose nonsteroidal antiinflammatory drug antiplatelet activity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>